Agents affecting bone mineral homeostasis Flashcards
Ca is controlled by 3 calcitropic hormones. What are they?
PTH, calcitonin, calcitriol (active Vd)
What are the 3 major sites of action for blood calcium regulation?
Bone, GI tract, Kidneys
What are the 3 major actions of PTH?
increase bone resorption, increase kidney reabsorption, increase active form of VD
PTH is released when concentration of Ca is _____ in the blood.
low
Activation of calcium sensor has what 2 main transducing effect?
Activation of Phospholipase C and inhibition of adenylyl cyclase
Where are PTH and Calcitonin secreting cells found?
parathyroid, and parafollicular cells in thyroid
Other than pT and thyroid, where else is the calcium sensor expressed?
kidney, osteoblasts, hematopoietic cells, Gi mucosa
Calcitonin functions to _____ plasma Ca.
decrease
3 major actions of calcitonin
decrease bone resorption, decrease kidney resorption, decrease active form of vitamin D.
In general, calcitonin _____ PTH actions.
opposes
Calcitriol acts to ____ plasma Ca.
increase
Where is calcitriol synthesized
skin and blood
What are the most important physiological actions of calcitriol?
increase calcium uptake from GI, increase kidney reabsoprtion, increase bone reabsoprtion
What can cause loss of Ca homeostasis?
estrogen deficiency, GC excess, GH deficiency, insulin deficiency, primary hypoparathydoidism, cancer
Response to low Ca
detected by PT–> release of PTH–> increase absorption at kidney, increased synthesis of calcitriol, increased resoprtion of bone, more calcitriol results in increased GI absorption
Response to high Ca
Detected by parafollicular cells causing release of calcitonin–> decreased synthesis of PTH, decreased resoprtion of bone, shift to inactive VD, decreased PTH causes increase excretion of calcium
PTH MOA
binds plasma membrane receptor, activates adenylyl cyclase, increase cAMP–> activates PK–> increased urine cAMP
What is the treatment for hypoparathyroidism?
bioengineered PTH, injectible daily form
MOA of teriparatide
HRpth1-34 directly stimulates bone formation without stimulating resorption. IMportant for women after bisphosphonate, may stimulate IGF-1
Uses of raloxifene
first SERM to be approved for osteoporosis. Has beneficial effects of estrogen without stimulating breast cancer.
____ is a monoclonal antibody to RANKK
denosumab
MOA of denosumab
blocks stimulation of osteocyte formation by RANKL and decreases osteoporosis. Increases bone mass in pt with breast or prostate cancer
What does FGF23 do?
inhibits formation of VD, opposes PTH in the kidney, produced by osteoblasts and clasts
MOA of calcitonin
binds to plasma membrane receptor, decreases ruffled border surface area on osteoclasts, not a global inhibitor of PTH, has direct renal effects